Abstract:Background: The use of single-chain variable fragments (scFvs) for treating human diseases, such as cancer and immune system disorders, has attracted significant attention. However, a critical drawback of scFv is its extremely short serum half-life, which limits its therapeutic potential. Thus, there is a critical need to prolong the serum half-life of the scFv for clinical applications. One promising serum half-life extender for therapeutic proteins is human serum albumin (HSA), which is the most abundant protein in human serum, known to have an exceptionally long serum half-life. However, conjugating a macromolecular half-life extender to a small protein, such as scFv, often results in a significant loss of its critical properties. Results: In this study, we conjugated the HSA to a permissive site of scFv to improve pharmacokinetic profiles. To ensure minimal damage to the antigen-binding capacity of scFv upon HSA conjugation, we employed a site-specific conjugation approach using a heterobifunctional crosslinker that facilitates thiol-maleimide reaction and inverse electron-demand Diels-Alder reaction (IEDDA). As a model protein, we selected 4D5scFv, derived from trastuzumab, a therapeutic antibody used in human epithermal growth factor 2 (HER2)-positive breast cancer treatment. We introduced a phenylalanine analog containing a very reactive tetrazine group (frTet) at conjugation site candidates predicted by computational methods. Using the linker TCO-PEG4-MAL, a single HSA molecule was site-specifically conjugated to the 4D5scFv (4D5scFv-HSA). The 4D5scFv-HSA conjugate exhibited HER2 binding affinity comparable to that of unmodified 4D5scFv. Furthermore, in pharmacokinetic profile in mice, the serum half-life of 4D5scFv-HSA was approximately 12 h, which is 85 times longer than that of 4D5scFv. Conclusions: The antigen binding results and pharmacokinetic profile of 4D5scFv-HSA demonstrate that the site-specifically albumin-conjugated scFv retained its binding affinity with a prolonged serum half-life. In conclusion, we developed an effective strategy to prepare site-specifically albumin-conjugated 4D5scFv, which can have versatile clinical applications with improved efficacy.

Enhancing the Pharmacokinetic Profile of Interleukin 2 through Site-Specific Conjugation to a Selective Small-Molecule Transthyretin Ligand

Protein Engineering Strategies for Improved Pharmacokinetics

Hydrophilic Small Molecules That Harness Transthyretin To Enhance the Safety and Efficacy of Targeted Chemotherapeutic Agents

Tuning protein half-life in mouse using sequence-defined biopolymers functionalized with lipids

Long-Acting Human Interleukin 2 Bioconjugate Modified with Fatty Acids by Sortase A

Engineering a Pharmacologically Superior Form of Granulocyte-Colony-stimulating Factor by Fusion with Gelatin-Like-protein Polymer.

Site-Specific Chemical Modification of a Cytokine Mimic for Small Molecule-Based Tumor Targeting.

Polymerization Induced Self-Assembly of a Site-Specific Interferon Α-Block Copolymer Conjugate into Micelles with Remarkably Enhanced Pharmacology

In vitro and in vivo Evaluation of Chemically Synthesized, Receptor-Biased Interleukin-4 and Photocaged Variants

Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins

Enhanced therapeutic potential of antibody fragment via IEDDA-mediated site-specific albumin conjugation

Phosphorylcholine Polymer Nanocapsules Prolong the Circulation Time and Reduce the Immunogenicity of Therapeutic Proteins

A Cytokine Receptor-Masked IL2 Prodrug Selectively Activates Tumor-Infiltrating Lymphocytes for Potent Antitumor Therapy

Site-specific in Situ Growth of an Interferon-Polymer Conjugate That Outperforms PEGASYS in Cancer Therapy.

Site-specific pegylated IL2 mutein with biased IL2 receptor binding for cancer immunotherapy

Sortase-mediated site-specific modification of interleukin-2 for the generation of a tumor targeting acetazolamide-cytokine conjugate

Directed disruption of IL2 aggregation sites produces designer biologics with enhanced specificity coupled to improved production capacity

Enzyme-Activatable Interferon–Poly(α-amino Acid) Conjugates for Tumor Microenvironment Potentiation

Half-life extended biotherapeutics

Sortase-Mediated Site-Specific Modification of Interleukin-2 for the Generation of a Tumor-Targeting Acetazolamide–Cytokine Conjugate

Protein-drug Conjugate Programmed by Ph-Reversible Linker for Tumor Hypoxia Relief and Enhanced Cancer Combination Therapy.